---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-001536"
form_type: "8-K"
ticker: "AIM"
cik: "0000946644"
company_name: "AIM ImmunoTech Inc."
filed_at: "2023-01-17T23:59:59+00:00"
generated_at: "2026-06-20T15:09:18.881861+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# AIM ImmunoTech enters into clinical research agreement with AstraZeneca and Erasmus MC for pancreatic cancer study

## Summary
- Collaboration to evaluate Ampligen (rintatolimod) combined with AstraZeneca's durvalumab in metastatic pancreatic ductal adenocarcinoma.
- Erasmus MC will sponsor and conduct a phase II, non-randomized, open-label, single-arm study (DURIPANC Study).
- AIM supplies rintatolimod; AstraZeneca supplies durvalumab; AIM retains all intellectual property rights.
- Erasmus owns study data but grants AIM unrestricted use; AIM owns inventions related to rintatolimod.
- Agreement terminable on completion, material breach, insolvency, or ethics committee rejection.

## SEC filing metadata
- accession: 0001493152-23-001536
- form_type: 8-K
- ticker: AIM
- cik: 0000946644
- company_name: AIM ImmunoTech Inc.
- filed_at: 2023-01-17T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/946644/000149315223001536/0001493152-23-001536-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/946644/000149315223001536/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-001536
- JSON: https://secwatch.observer/filing/0001493152-23-001536.json
- Plain text: https://secwatch.observer/filing/0001493152-23-001536.txt

## Key facts
- Material Agreements
  AIM ImmunoTech Inc. entered into external sponsored collaborative clinical research agreement with Erasmus University Medical Center Rotterdam and AstraZeneca BV (effective 2023-01-13).
  - Action: entry
  - Agreement: collaboration
  - Counterparty: Erasmus University Medical Center Rotterdam and AstraZeneca BV
  - Effective: 2023-01-13
  source text: On January 13, 2023, we entered into an external sponsored collaborative clinical research agreement with Erasmus University Medical Center Rotterdam and AstraZeneca BV, pursuant to which Erasmus is sponsoring and planning to perform an investigator-initiated clinical study, entitled Combining anti-PD-L1 immune checkpoint inhibitor durvalumab with TLR-3 agonist rintatolimod in patients with metastatic pancreatic ductal adenocarcinoma for therapy effect (the “Study”) in which it will use both study drugs provided by AstraZeneca and us.
  evidence_url: https://www.sec.gov/Archives/edgar/data/946644/000149315223001536/0001493152-23-001536-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.